Evidence map›Paper›PMID 42230962›Full record

GuidelineBone marrow transplantation2026

HLA matching in contemporary haematopoietic cell transplantation: Recommendations from the EBMT Practice Harmonisation and Guidelines Committee.

Esteban Arrieta-Bolaños, Alberto Cardoso Martins Lima, Marco Andreani, Dianne De Santis, Florent Malard, Neema P Mayor, Rohtesh S Mehta, Roland Meisel, Simona Pagliuca, Effie Petersdorf and 12 more

Abstract readPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Bone marrow transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Esteban Arrieta-BolañosInstitute for Experimental Cellular Therapy, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.ORCID http://orcid.org/0000-0002-3696-5803
Alberto Cardoso Martins LimaImmunogenetics Institute (IGEN), Associação Fundo de Incentivo à Pesquisa, São Paulo; Histocompatibility Laboratory, Complexo Hospital de Clínicas, Federal University of Paraná, Curitiba, Brazil.ORCID http://orcid.org/0000-0002-7248-7060
Marco AndreaniLaboratory of Transplant Immunogenetics, Department of Hematology/Oncology, Cell and Gene Therapy, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.ORCID http://orcid.org/0000-0003-3451-3624
Dianne De SantisDepartment of Clinical Immunology, Path West, Perth, WA, Australia.
Florent MalardService d'Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, Sorbonne Université, INSERM UMRs 938 Centre de Recherche Saint-Antoine, Paris, France.ORCID http://orcid.org/0000-0002-3474-0002
Neema P MayorAnthony Nolan Research Institute, Royal Free Hospital, London, UK.ORCID http://orcid.org/0000-0002-9226-143X
Rohtesh S MehtaDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-8532-544X
Roland MeiselDivision of Pediatric Stem Cell Therapy, Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany.ORCID http://orcid.org/0000-0001-5230-0628
Simona PagliucaDepartment of Hematology, Nancy University Hospital & CNRS UMR7365 IMoPA, University of Lorraine, Vandoeuvre-lès-Nancy-France, Nancy, France.
Effie PetersdorfDivision of Translational Science and Therapeutics, Fred Hutchinson Cancer Center, Seattle, Washington; Department of Medicine, University of Washington, Seattle, USA.
Simona PiemonteseHematology and BMT Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.ORCID http://orcid.org/0000-0002-5908-0792
Nicoletta SacchiItalian Bone Marrow Donor Registry, EO Ospedali Galliera di Genova, Genoa, Italy.
Nicole SantoroHematology Unit, Department of Oncology and Hematology, Pescara Hospital, Pescara, Italy; Department of Medicine and Aging Sciences, University of Chieti-Pescara, Chieti, Italy.ORCID http://orcid.org/0000-0001-5705-8084
Jaime SanzHematology Department, Hospital Universitari i Politècnic La Fe, Valencia Departament de Medicina Universitat de Valencia, CIBERONC, Instituto Carlos III, Madrid, Spain.ORCID http://orcid.org/0000-0001-6934-4619
Johannes ScheteligDepartment of Internal Medicine I, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany.ORCID http://orcid.org/0000-0002-2780-2981
Stephen R SpellmanCIBMTR® (Center for International Blood and Marrow Transplant Research), NMDP, Minneapolis, MN, USA.
Francesco OnidaCo-Chair of the Practice Harmonisation and Guidelines Committee of the EBMT, Hematology & ASCT Unit, ASST Fatebenefratelli-Sacco, University of Milan, Milan, Italy.
Isabel Sánchez-OrtegaSecretary of the Practice Harmonisation and Guidelines Committee of EBMT EBMT Medical Officer, Executive Office, Barcelona, Spain.ORCID http://orcid.org/0009-0005-5519-9154
Mohamad MohtyService d'Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, Sorbonne Université, INSERM UMRs 938 Centre de Recherche Saint-Antoine, Paris, France.ORCID http://orcid.org/0000-0002-7264-808X
Ibrahim Yakoub-AghaChair of the EBMT Practice Harmonisation and Guidelines Committee CHU de Lille, Univ Lille, INSERM U1286, Infinite, 59000, Lille, France.
Katharina Fleischhauer *Institute for Experimental Cellular Therapy, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.ORCID http://orcid.org/0000-0002-5827-8000
Annalisa Ruggeri *Hematology and BMT Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy. annalisaruggeri80@hotmail.com.ORCID http://orcid.org/0000-0002-7261-2765

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

HLA compatibility has been a cornerstone for safe and successful allogeneic haematopoietic cell transplantation (HCT), with human leukocyte antigen (HLA)-mismatched transplants consistently associated with inferior survival. However, recent advances in typing technologies, supportive care, and novel graft-versus-host disease (GvHD) prophylaxes have prompted the revisiting of HLA mismatch relevance in contemporary HCT. Within the framework of the 3

Indexed as

Hematopoietic Stem Cell TransplantationHistocompatibility TestingHLA AntigensGraft vs Host DiseaseHumansHLA Antigens

Identifiers

PMID42230962
PMCPMC13437245

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.